{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:45:48Z","timestamp":1761489948107},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5796","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T18:05:47Z","timestamp":1457978747000},"page":"629-634","source":"Crossref","is-referenced-by-count":8,"title":["Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease"],"prefix":"10.2169","volume":"55","author":[{"given":"Akihiro","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Saijo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyoshi","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shuin","sequence":"additional","affiliation":[{"name":"Department of Urology, Kochi Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Shimodaira","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan"},{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7: 277-288, 2010.","DOI":"10.1038\/nrclinonc.2010.42"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 36: 337-343, 2006.","DOI":"10.1093\/jjco\/hyl052"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55-64, 2015.","DOI":"10.1038\/nrc3844"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45: 860-867, 2013.","DOI":"10.1038\/ng.2699"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939, 2011.","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318, 2009.","DOI":"10.1200\/JCO.2008.19.5511"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.","DOI":"10.1056\/NEJMoa065044"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068, 2010.","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.","DOI":"10.1016\/S0140-6736(07)61904-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513, 2011.","DOI":"10.1056\/NEJMoa1003825"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.","DOI":"10.1056\/NEJMoa1009290"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31: 521-537, 2010.","DOI":"10.1002\/humu.21219"},{"key":"13","unstructured":"13. Bosman FT, Carneiro F, Hruban R, Theise N. WHO Classification of Tumours of the Digestive System. 4th ed. International Agency for Research on Cancer (IARC), Lyon, 2010."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745, 2007.","DOI":"10.1038\/nrd2380"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.","DOI":"10.1056\/NEJMoa066838"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22: 2661-2666, 2011.","DOI":"10.1093\/annonc\/mdr011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim HC, Lee JS, Kim SH, So HS, Woo CY, Lee JL. Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer Res Treat 45: 349-353, 2013.","DOI":"10.4143\/crt.2013.45.4.349"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Roma A, Maruzzo M, Basso U, et al. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer 14: 309-316, 2015.","DOI":"10.1007\/s10689-014-9771-y"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ito T, Okusaka T, Nishida T, et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31: 1265-1274, 2013.","DOI":"10.1007\/s10637-012-9910-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G. Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16: 1422-1428, 2012.","DOI":"10.1007\/s11605-012-1847-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Igarashi H, Ito T, Nishimori I, et al. Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey. J Gastroenterol 49: 511-516, 2014.","DOI":"10.1007\/s00535-013-0794-1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5796\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:18:41Z","timestamp":1498277921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5796\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5796","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}